Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Monia Marchetti

Showing results (61-70 of 123) with videos related to

Pageof 13
Sort By:
British Journal of Haematology|July 10, 2018
The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinibElena Crisà, Daniela Cilloni, Elena M Elli, et al.
American Journal of Hematology|December 3, 2025
A Novel, Ruxolitinib-Sensitive, CCDC6::JAK2 Fusion Gene in a Patient With Atypical, JAK2 Unmutated, Polycythemia Vera-Like, Myeloproliferative NeoplasmNiccolò Bartalucci, Danilo Tarantino, Giuseppe G Loscocco, et al.
American Journal of Hematology|March 24, 2017
Identification of new BMP6 pro-peptide mutations in patients with iron overloadChiara Piubelli, Annalisa Castagna, Giacomo Marchi, et al.
Cytotherapy|October 31, 2013
Kinetics of the use of cryopreserved autologous stem cell grafts: a GITMO-SIDEM surveyJacopo Olivieri, Luca Pierelli, Martino Introna, et al.
The Lancet. Haematology|July 5, 2024
Diagnosis and management of Evans syndrome in adults: first consensus recommendationsBruno Fattizzo, Monia Marchetti, Marc Michel, et al.
Blood Cancer Journal|November 24, 2025
European LeukemiaNet criteria for safety and efficacy evaluation of new drugs for myelofibrosisMonia Marchetti, Alessandro Maria Vannucchi, John O Mascarenhas, et al.
Blood|August 23, 2007
JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosisGiovanni Barosi, Gaetano Bergamaschi, Monia Marchetti, et al.
Blood Cancer Journal|January 19, 2022
Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patientsCinzia Borgogna, Riccardo Bruna, Gloria Griffante, et al.
Blood|July 5, 2005
Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET)Giovanni Barosi, Dominique Bordessoule, Jean Briere, et al.
The Lancet. Haematology|March 31, 2022
Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendationsMonia Marchetti, Alessandro Maria Vannucchi, Martin Griesshammer, et al.
Pageof 13

Showing results (61-70 of 123) with videos related to

Sort By:
Pageof 13
British Journal of Haematology|July 10, 2018
The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinibElena Crisà, Daniela Cilloni, Elena M Elli, et al.
American Journal of Hematology|December 3, 2025
A Novel, Ruxolitinib-Sensitive, CCDC6::JAK2 Fusion Gene in a Patient With Atypical, JAK2 Unmutated, Polycythemia Vera-Like, Myeloproliferative NeoplasmNiccolò Bartalucci, Danilo Tarantino, Giuseppe G Loscocco, et al.
American Journal of Hematology|March 24, 2017
Identification of new BMP6 pro-peptide mutations in patients with iron overloadChiara Piubelli, Annalisa Castagna, Giacomo Marchi, et al.
Cytotherapy|October 31, 2013
Kinetics of the use of cryopreserved autologous stem cell grafts: a GITMO-SIDEM surveyJacopo Olivieri, Luca Pierelli, Martino Introna, et al.
The Lancet. Haematology|July 5, 2024
Diagnosis and management of Evans syndrome in adults: first consensus recommendationsBruno Fattizzo, Monia Marchetti, Marc Michel, et al.
Blood Cancer Journal|November 24, 2025
European LeukemiaNet criteria for safety and efficacy evaluation of new drugs for myelofibrosisMonia Marchetti, Alessandro Maria Vannucchi, John O Mascarenhas, et al.
Blood|August 23, 2007
JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosisGiovanni Barosi, Gaetano Bergamaschi, Monia Marchetti, et al.
Blood Cancer Journal|January 19, 2022
Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patientsCinzia Borgogna, Riccardo Bruna, Gloria Griffante, et al.
Blood|July 5, 2005
Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET)Giovanni Barosi, Dominique Bordessoule, Jean Briere, et al.
The Lancet. Haematology|March 31, 2022
Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendationsMonia Marchetti, Alessandro Maria Vannucchi, Martin Griesshammer, et al.
Pageof 13